Table 1.

Randomized controlled trials of medication treatment for vascular dementia included in this review

Source, Reference, Year	No. of Patients, Age	Medication	Trial Length in Weeks	Primary Outcomes
Wilkinson, et al. [71], 2003	n = 616 Mean age, 75 years	Donepezil	24	2.2-Point improvement on the ADAS-cog among treated patients (10 mg dose) vs a 0.1-point improvement for those receiving placebo (2.1-point treatment difference; p < 0.001); 1.8-point improvement on the ADAS-cog among treated patients (5 mg dose) vs placebo (1.7-point treatment difference; p < 0.01). Patients treated with 5 mg (39%) and those treated with 10 mg (32%) showed improvement on the CIBIC-plus vs 25% of those receiving placebo (p = 0.004 for 5 mg comparison, and p = 0.047 for 10 mg)
Black, et al. [70], 2003	n = 603 Mean age, 74 years	Donepezil	24	2.0-Point improvement on the ADAS-cog among treated patients (10 mg dose) vs a 0.3-point decrease for those receiving placebo (2.3-point treatment difference; P < 0.001); 1.6-point improvement on the ADAS-cog among treated patients (5 mg dose) vs placebo (1.9-point treatment difference; p < 0.01). Patients treated with 5 mg (38%) and those treated with 10 mg (31%) showed improvement on the CIBIC-plus vs 32% of those receiving placebo (p < 0.05 for 5 mg comparison, but not significant for 10 mg comparison)
Roman, et al. [72], 2010	n = 974, Mean age, 73 years	Donepezil	24	1.0-Point improvement on the V-ADAS-cog among treated patients (5 mg dose) vs a 0.1-point decrease for those receiving placebo (1.2-point treatment difference; P < 0.01); no significant difference in the CIBIC-plus score
Auchus, et al. [79], 2007	n = 788 Mean age, 72 years	Galantamine	26	1.8-Point improvement on the ADAS-cog among treated patients vs a 0.3-point improvement for those receiving placebo (1.5-point treatment difference; p < 0.001); no significant difference in the ADCS-ADL score
Ballard, et al. [82], 2008	n = 710 Mean age, 73 years	Rivastigmine	24	0.7-Point improvement on the V-ADAS-cog among treated patients vs a 0.6-point decrease for those receiving placebo (1.3-point treatment difference; p = 0.028); no significant difference in the ADCS-CGIC score
Orgogozo, et al. [86], 2002	n = 321 Mean age, 76 years	Memantine	28	0.4-Point improvement on the ADAS-cog among treated patients vs a 1.6-point decline for those receiving placebo (2.0-point treatment difference; p = 0.002); no significant difference in the CIBIC-plus score
Wilcock, et al. [87], 2002	n = 579 Mean age, 77 years	Memantine	28	0.5-Point decline on the ADAS-cog among treated patients vs a 2.3-point decline for those receiving placebo (1.8-point treatment difference; p < 0.001); no significant difference in the CGIC score.

Vascular dementia (VaD) was determined by the National Institute of Neurological Disorders and Stroke (NINDS) and the Association Internationale pour la Recherche et l’Enseignement en Neurosciences (NINDS-AIREN) criteria for vascular dementia and computed tomography or magnetic resonance imaging evidence in all trials. The Vascular-Alzheimer’s Disease Assessment Scale-cognitive subscale (V-ADAS-cog) comprises the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) plus the Maze and Number Cancellation test (NCT) to assess executive function

ADCS-ADL = Alzheimer’s Disease Cooperative Study-Activities of Daily Living inventory total score; ADCS-CGIC = Alzheimer’s Disease Cooperative Study-Clinician’s Global Impression of Change; CGIC = Clinical Global Impression of Change; CIBIC-plus = Clinician’s Interview-Based Impression of Change plus Caregiver Input